Ranbaxy’s Valsartan ANDA Wins FDA Approval After Lengthy Delay
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory nod gives Ranbaxy green light to launch its generic version of Novartis’ Diovan with 180-day exclusivity; other ANDA holders may continue to challenge Ranbaxy’s hold on the market.